Pharmacological targeting of SMAD3 activity, such as with SIS3 (a specific inhibitor of SMAD3 C-terminal phosphorylation), was proposed as a potential therapeutic strategy to treat various diseases, including metastatic cancer (57). The gene discussed is SMAD3; the disease is metastatic malignant neoplasm.